We are live on !
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
Turnover
44%
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.15%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
+$170M
(+96%)
Cap. Flow
+$85.9M
Cap. Flow % of AUM
Cap. Flow %
24.81%
Top 10 Holdings %
Top 10 Hldgs %
43.57%
Holding
90
New
39
Increased
14
Reduced
5
Closed
27
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACOR
Acorda Therapeutics
ACOR
|
+$8.81M |
| 2 |
Edwards Lifesciences
EW
|
+$8.72M |
| 3 |
Biogen
BIIB
|
+$7.91M |
| 4 |
bluebird bio
BLUE
|
+$7.43M |
| 5 |
CONMED
CNMD
|
+$7.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$6.74M |
| 2 |
Pacific Biosciences
PACB
|
+$5.95M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$5.68M |
| 4 |
Sage Therapeutics
SAGE
|
+$5.34M |
| 5 |
iShares US Healthcare Providers ETF
IHF
|
+$4.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.94% |
| 2 | Miscellaneous | 40.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
iShares Russell 2000 ETF
IWM
$79.1B
| $40.2M | 11.62% |
350,000
+275,000
| +367% | +$31M |
2016 Q1
1 quarter
|
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $21.6M | 6.25% |
400,000
+180,000
| +82% | +$9.9M |
2016 Q1
1 quarter
|
|
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| $20.9M | 6.05% |
+100,000
| New | +$20.7M |
2016 Q2
0 quarters
|
|
|
GWPH
4
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $11.9M | 3.44% |
+130,000
| New | +$10.9M |
2016 Q2
0 quarters
|
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11M | 3.17% |
215,000
+95,000
| +79% | +$4.72M |
2016 Q1
1 quarter
|
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $10.5M | 3.03% |
90,000
+50,000
| +125% | +$7.09M |
2016 Q1
1 quarter
|
|
|
NUVA
7
DELISTED
NuVasive, Inc.
NUVA
| $8.96M | 2.59% |
150,000
+80,000
| +114% | +$4.32M |
2014 Q3
7 quarters
|
|
8
Medtronic
MDT
$122B
| $8.68M | 2.51% |
100,000
+73,422
| +276% | +$5.94M |
2016 Q1
1 quarter
|
|
9
BioMarin Pharmaceuticals
BMRN
$10.8B
| $8.56M | 2.47% |
110,000
+70,000
| +175% | +$5.95M |
2016 Q1
1 quarter
|
|
|
10
Edwards Lifesciences
EW
$51.3B
| $8.48M | 2.45% |
+255,000
| New | +$8.72M |
2016 Q2
0 quarters
|
|
|
11
CONMED
CNMD
$1.48B
| $8.35M | 2.41% |
+175,000
| New | +$7.41M |
2016 Q2
0 quarters
|
|
|
ACOR
12
DELISTED
Acorda Therapeutics
ACOR
| $8.29M | 2.39% |
+2,708
| New | +$8.81M |
2016 Q2
0 quarters
|
|
13
CALL
Boston Scientific
BSX
$66.2B
| $8.18M | 2.36% |
+350,000
| New | +$7.57M |
2016 Q2
0 quarters
|
|
|
14
Boston Scientific
BSX
$66.2B
| $7.6M | 2.19% |
325,000
-125,000
| -28% | -$2.7M |
2016 Q1
1 quarter
|
|
|
SIOX
15
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $7.38M | 2.13% |
+71,875
| New | +$7.18M |
2016 Q2
0 quarters
|
|
|
16
DELISTED
bluebird bio
BLUE
| $7.36M | 2.13% |
+13,124
| New | +$7.43M |
2016 Q2
0 quarters
|
|
|
17
Biogen
BIIB
$37B
| $7.26M | 2.1% |
+30,000
| New | +$7.91M |
2016 Q2
0 quarters
|
|
|
SPNC
18
DELISTED
Spectranetics Corp
SPNC
| $7.02M | 2.03% |
375,000
+25,000
| +7% | +$440K |
2015 Q3
3 quarters
|
|
|
CLVS
19
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.86M | 1.98% |
+500,000
| New | +$7.31M |
2016 Q2
0 quarters
|
|
|
CLVS
20
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.17M | 1.78% |
450,000
+431,500
| +2,332% | +$6.31M |
2016 Q1
1 quarter
|
|
21
DELISTED
NEVRO CORP.
NVRO
| $5.9M | 1.7% |
80,000
+5,000
| +7% | +$339K |
2015 Q4
2 quarters
|
|
22
PUT
Sarepta Therapeutics
SRPT
$1.87B
| $5.72M | 1.65% |
+300,000
| New | +$5.56M |
2016 Q2
0 quarters
|
|
23
Neurocrine Biosciences
NBIX
$14.5B
| $5.68M | 1.64% |
+125,000
| New | +$5.75M |
2016 Q2
0 quarters
|
|
24
Iovance Biotherapeutics
IOVA
$6.38B
| $5.67M | 1.64% |
700,000
+450,000
| +180% | +$2.83M |
2016 Q1
1 quarter
|
|
25
DELISTED
K2M Group Holdings, Inc
KTWO
| $5.43M | 1.57% |
+350,000
| New | +$4.94M |
2016 Q2
0 quarters
|
|
Similar funds
AFS
E
Ghost Tree Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Ghost Tree Capital held 90 positions worth $346M, up 96% from $177M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Ghost Tree Capital deployed $85.9M of net new capital in Q2 2016, opening 39 new positions and adding to 14 existing holdings. Its largest new stake was Acorda Therapeutics: 2,708 shares worth $8.29M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Celgene Corp, an estimated $6.74M trimmed.
- Ghost Tree Capital's largest Q2 2016 buy was Acorda Therapeutics: 2,708 shares worth $8.29M.
- Ghost Tree Capital added most to Alexion Pharmaceuticals in Q2 2016, an estimated $7.09M increase.
- Ghost Tree Capital's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $6.74M.
- Ghost Tree Capital fully exited Pacific Biosciences in Q2 2016, selling an estimated $5.95M.
- Ghost Tree Capital's ten largest holdings make up 44% of its $346M portfolio in Q2 2016.
- Ghost Tree Capital opened 39 new positions and closed 27 in Q2 2016.
- Ghost Tree Capital's portfolio value rose 96% quarter-over-quarter to $346M.
Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.